Olpruva | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

7 results for “Olpruva”

Drugs

Phenylbutyric acid(Ammonaps, Buphenyl, Olpruva 2 Gm Pack, Pheburane, Relyvrio, Albrioza)

Conditions: Amyotrophic Lateral Sclerosis (ALS), Argininosuccinate Synthetase Deficiency (Citrullinemia) +4 more

C₁₀H₁₂O₂ · Rx

News

Zevra Therapeutics Highlights FDA Approval of MIPLYFFA and Outlines Strategic Vision for Growth

Zevra Therapeutics Receives Buy Rating Following FDA Approval of Miplyffa for Niemann-Pick Disease Type C

Zevra Therapeutics Reports Positive Q3 2024 Results Driven by MIPLYFFA Approval